X

Trial Profile

A phase II study of mifepristone (RU-486) in androgen independent prostate cancer with correlative assessment of androgen receptor co-repressor proteins

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mifepristone (Primary)
Indications Prostate cancer
Focus Therapeutic Use

Most Recent Events

06 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
19 Dec 2007 Status changed from completed to in progress (primary outcome completion date June 2006; study completion date June 2009).
06 Oct 2006 Status change

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com